Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Lisa M. Coussens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2389-1865; OpenAlex author ID A5025353193; NIH RePORTER profile ID 1872813. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 1)
Trials
0
Grants
2
Labs led
0
Collaborators
130
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper, 1 grant · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers, 1 grant

Papers 23

  1. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  2. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  3. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  4. Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer. Co-author DOI 10.3389/fimmu.2026.1894080↗
  5. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  6. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.02.07.632847↗
  7. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  8. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  9. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
  10. Correction: Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognosti… Co-author DOI 10.1158/0008-5472.can-24-2929↗
  11. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0873↗
  12. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2022-005425↗
  13. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. Co-author DOI 10.1158/0008-5472.can-22-1190↗
  14. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  15. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  16. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  17. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Last author DOI 10.1158/2159-8290.cd-20-0841↗
  18. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.20.00287↗
  19. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  20. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  21. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗
  22. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-4192↗
  23. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. Co-author DOI 10.1186/s40425-018-0435-6↗

Grants 2

  1. Community Outreach and Engagement P30CA069533↗
  2. Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 9 shared papers, 1 shared grant, 2021–2026 · strength 2.10
  2. Jonathan Robert Brody · 6 shared papers, 1 shared grant, 2023–2026 · strength 1.67
  3. Katie E. Blise · 7 shared papers, 2024–2026 · strength 1.40
  4. Charles D. Lopez · 6 shared papers, 2021–2026 · strength 1.01
  5. Elizabeth M. Jaffee · 8 shared papers, 2018–2024 · strength 1.00
  6. Shannon M. Liudahl · 7 shared papers, 2019–2024 · strength 0.87
  7. Kevin Hawthorne · 4 shared papers, 2025–2026 · strength 0.76
  8. Brian J Druker · 1 shared grant, 2026 · strength 0.71
  9. Paul T. Spellman · 1 shared grant, 2026 · strength 0.71
  10. Melissa H. Wong · 1 shared grant, 2026 · strength 0.71
  11. Luiz Eduardo Bertassoni · 1 shared grant, 2026 · strength 0.71
  12. Jackilen Shannon · 1 shared grant, 2026 · strength 0.71
  13. Emek Demir · 1 shared paper, 1 shared grant, 2023–2025 · strength 0.69
  14. Robert L Eil · 3 shared papers, 2025–2026 · strength 0.66
  15. Zheng Xia · 3 shared papers, 2025–2026 · strength 0.65
  16. Canping Chen · 3 shared papers, 2025–2026 · strength 0.65
  17. Terry K. Morgan · 5 shared papers, 2019–2025 · strength 0.60
  18. Katherine R. Pelz · 4 shared papers, 2019–2026 · strength 0.55
  19. Gordon Brent Mills · 3 shared papers, 2025–2026 · strength 0.54
  20. Jason M. Link · 4 shared papers, 2021–2025 · strength 0.52
  21. Katelyn T. Byrne · 3 shared papers, 2021–2026 · strength 0.50
  22. Patrick Joseph Worth · 3 shared papers, 2025 · strength 0.49
  23. Isabel A. English · 3 shared papers, 2025 · strength 0.49
  24. Motoyuki Tsuda · 3 shared papers, 2025 · strength 0.49
  25. Andressa Dias Costa · 4 shared papers, 2021–2024 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.